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BACKGROUND
Benzocaine is a topical anesthetic frequently used in
healthcare facilities and in over-the-counter
medications in concentrations up to 20%.1 Benzocaine
may induce methemoglobinemia, a condition that
impairs the blood’s ability to carry oxygen.2 The
optimal management of exposure to benzocaine
remains unclear because serious toxicity is uncommon
and may not be dose-related.1,3 In 2000, it was
estimated that more than one million exposures to
benzocaine, both therapeutic and unintentional, occur
yearly in the US; yet fewer than 100 cases of
benzocaine-induced methemoglobinemia have been
reported in the medical literature over the last 50
years.1,4 Considerable under-reporting of cases
probably exists, as patients with mild
methemoglobinemia may have minimal symptoms or
remain asymptomatic. Severe cases requiring
treatment are evidently quite unusual.
Poison Control Centers (PCCs) are often consulted
after exposure to benzocaine and make
recommendations for home observation or for
evaluation in a healthcare facility (HCF). The
experience of one of the investigators (JS) is that many
PCCs recommend HCF observation for several hours
following benzocaine ingestion to detect delayed
development of methemoglobinemia. If benzocaine-
induced methemoglobinemia truly is rare, then such
conservative recommendations may be unwarranted
in the majority of cases. In addition, patients may be
subjected to unnecessary expenditures of time and
money, as well as the potential risks of diagnostic
medical interventions.
We sought to determine if a consensus exists among
PCC recommendations for managing benzocaine
exposures. We presented two hypothetical cases of
pediatric benzocaine exposure to PCCs in the United
States and Canada to find out what their
recommendations would be in relation to several
factors, including: the need for observation, where and
for how long such observation should occur, the need
for gastrointestinal decontamination, the methods of
evaluating for methemoglobinemia, and the indications
for treatment with methylene blue.
METHODS
A single investigator (SR) conducted a telephone
survey of PCCs in the United States and Canada in
February 2001. The list of PCCs was obtained from
the American Association of Poison Control Centers
(AAPCC) website (www.aapcc.org). Although
Canadian PCCs are not members of the AAPCC,
their contact information was obtained from the same
website and their customary practices are similar to
PCCs in the United States. Persons answering the
general poison information line of each PCC were
asked if they wished to voluntarily participate in the
survey, and were given the option of having the
investigator call back at a more convenient time or to
have another PCC staff member voluntarily complete
the survey instead. Participants were also informed
that their responses would be recorded in an
anonymous fashion. We chose to have the first
available volunteer complete the survey whenever
possible, rather than a PCC manager or medical
director, as we felt this would better represent the
actual recommendations received by members of the
public with similar inquiries. The survey instrument (seePage 56 The California Journal of Emergency Medicine V:3, Jul-Sep 2004
Table 1) consisted of management questions related
to two hypothetical pediatric benzocaine exposures
and asked whether that PCC had a written policy or
protocol for management of benzocaine exposures.
Descriptive statistics were used for reporting the
results.
RESULTS
Sixty-two out of a total of 76 PCCs completed the
survey, for a response rate of 82%. Results are
presented in Table 2.
DISCUSSION
Survey respondents generally used the same reference,
Poisindex®, as their primary source of information in
managing benzocaine exposures, yet PCC
recommendations varied considerably. Poisindex®
states that the threshold toxic dose for benzocaine is
22-40 mg/kg.5 Many PCCs appeared to interpret this
information conservatively, resulting in the median
recommended threshold dose warranting observation
or any interventions occurring at the low end of this
range.
Almost 15% of PCCs did not give dose-dependent
recommendations, and appeared to believe that
significant methemoglobinemia is idiosyncratic or
related to altered drug metabolism. Sub-clinical
methemoglobinemia regularly occurs with therapeutic
benzocaine use, while significant methemoglobinemia
warranting treatment is rather uncommon.3 If
benzocaine-induced methemoglobinemia were dose-
Table 1. Survey instrument for PCC benzocaine management
Scenario 1:
A mother finds her 2-year-old toddler eating the contents of a 10 mL tube of teething gel containing
10% benzocaine. The child is initially crying, but is easily consoled, and otherwise appears normal and is
asymptomatic 10 minutes after exposure.
1) Do your recommendations depend on the estimated ingested dose?
a. (If Yes) What is your threshold dose for changing your recommendations?
2) Would you recommend any gastrointestinal decontamination for this child?
a. (If Yes) What type?
3) Does this patient require a period of observation?
a. For how long?
b. Should observation occur at home or in a healthcare facility?
c. (If Home) What could happen that would make you then recommend transfer to a healthcare
facility?
d. (If HCF) What would you recommend occur at the healthcare facility?
Scenario 2:
Another 2-year-old ingested an over-the-counter product with 20% benzocaine 1 hour ago. He is
reportedly asymptomatic, but the mother thinks his color is “a little funny”.
1) Does abnormal coloration require the patient to be evaluated in a healthcare facility?
a. (If Yes) What should be done?
2) Does normal pulse oximetry effectively rule out methemoglobinemia?
3) What would the methemoglobin level have to be for you to recommend treatment in this asymptomatic
child?
4) Is it possible to be cyanotic and have methemoglobinemia, but NOT need treatment?
Other Questions:
1) Does your Poison Control Center have a written policy or protocol regarding the management of
benzocaine exposures?
a. (If Yes) Would you be willing to FAX us a copy of it?
2) What is the source of the data upon which your recommendations are based?Page  57 The California Journal of Emergency Medicine V:3, Jul-Sep 2004
Table 2. Summary of PCC survey results regarding benzocaine management (n=62 unless
otherwise indicated)
· Most recommendations (53/62=85%) depended on the Estimated Ingested Dose; the remaining nine
centers commented that benzocaine-induced methemoglobinemia was idiosyncratic and/or related to
alterations in cytochrome P450-mediated drug metabolism.
· The Threshold Dose for recommending observation or any interventions ranged
from 5-40 mg/kg.
· The median threshold dose for recommending observation was 22 mg/kg.
· Nine of the centers (15%) recommended a lower threshold for patients £ 1 yr old.
· GI Decontamination of asymptomatic patients was recommended by:
· 23 PCCs (37%) for patients observed at home
· 41 PCCs (66%) for non-cyanotic patients evaluated in HCFs
· 40 PCCs (65%) for cyanotic patients evaluated in HCFs
· The recommended Observation Period ranged from 0.5 to 24 hours.
· Most PCCs gave a range of hours (minimum to maximum number of hours).
· The mean minimum observation period was 3.1 hours overall (median 2 hours).
· The mean maximum observation period for HCF patients was 3.4 hours (median 4 hours).
· The most commonly recommended Signs to Observe for were:
· Cyanosis (61=98% of PCCs made this recommendation)
· Respiratory distress (47=76%)
· Altered level of consciousness (41=66%)
· Less commonly recommended signs to observe for include the ability to tolerate oral liquids (8=13%),
gastrointestinal symptoms such as nausea or vomiting (8=13%), seizures (7=11%), and lethargy
(3=5%). For each of the following one PCC recommended observation: anemia, ataxia, hypotension,
tachycardia, Down’s Syndrome, headache, and “any change”.
· Pulse Oximetry was recommended by 25 PCCs (40%) for asymptomatic non-cyanotic patients
and by 32 PCCs (52%) for asymptomatic cyanotic patients. Of note, eight PCCs (13%)
explicitly stated that pulse oximetry may be inaccurate with methemoglobinemia, and two
PCCs (3%) stated that normal pulse oximetry rules out methemoglobinemia.
· Arterial Blood Gas sampling was recommended by 29 PCCs (47%) for asymptomatic non-cyanotic
patients and by 47 PCCs (76%) for asymptomatic cyanotic patients. Only 1 PCC suggested venous blood
gas sampling as an alternative to arterial puncture.
· The recommended minimum Methemoglobin Level Warranting Treatment ranged from 10%
(generally asymptomatic) to 70% (often lethal) with a mean level of 24% and a median level of 20%.
Four PCC respondents (6.5%) did not recognize that a patient could be cyanotic with methemoglobin-
emia, yet not require treatment.
· Poisindex® was the most common data source (55=89%) used by PCCs for managing benzocaine expo-
sures.
· 13 PCCs (21%) had a written protocol for managing benzocaine exposures and nine of these centers
identified Poisindex® as their primary protocol reference.Page 58 The California Journal of Emergency Medicine V:3, Jul-Sep 2004
dependent, one would expect to see it more frequently
in the clinical setting, as the drug is used for several
indications and in widely varying doses. It is therefore
logical to infer that clinically-significant
methemoglobinemia represents an idiosyncratic
reaction. However, despite an extensive search of the
medical literature, we were not able to locate any
published human studies supporting this theory. Some
animal data supports the hypothesis that
methemoglobinemia is idiosyncratic. Eight sheep
treated with 56 to 112 mg benzocaine had
methemoglobin levels of 22.6±1.8% within 20 minutes
(responders), while four other sheep did not develop
methemoglobinemia (non-responders).6
Since most pediatric benzocaine exposures result in
little or no toxicity, our results are somewhat
concerning. Many PCC recommendations would
result in prolonged observation, gastrointestinal
decontamination, HCF evaluation, and painful or
potentially risky interventions (e.g. arterial blood gas
sampling), without good supporting evidence of
efficacy or necessity. Some outlying results among the
recommendations received are of particular concern,
including observation for up to 24 hours and not
treating methemoglobinemia until it reaches 70%, a
level that is often lethal. Although recommendations
generally clustered around those provided by
Poisindex®, there is no firm consensus among American
and Canadian PCCs in the management of pediatric
benzocaine exposures. The only item on our survey
that the great majority (>80%) of respondents agreed
upon was that cyanosis was the primary physical sign
to observe for among patients exposed to excessive
benzocaine doses. Although our results apparently
show some general consensus, they should not
therefore be taken as the standard of care, as they
have not been subject to any validation.
Research to determine the etiology and toxicokinetics
of benzocaine-induced methemoglobinemia could be
used to establish evidence-based recommendations
for managing such exposures in the future. One
potential method of investigation would be to
administer benzocaine to subjects pre-treated with
different cytochrome P450—or other metabolic
enzyme—inhibitors. In vitro or animal studies may be
necessary, since, as with all toxicologic research,
volunteer human studies may be difficult or impossible
to conduct in a safe and ethical manner.
Our study is limited by several factors. First, our survey
does not necessarily reflect the responses that would
be obtained in cases of actual benzocaine exposures.
We attempted to mitigate this factor by obtaining
responses from the first available person at each PCC
whose normal duties would be to answer such queries
from the public. Of note, some of the PCCs who opted
not to respond to the survey stated that it is their policy
not to answer questions relating to hypothetical toxic
exposures. The effects of such non-responders are
unclear; but given our 82% response rate, it is unlikely
to alter the results to a great degree. Secondly, no
attempt was made to detect any correlation between
the PCC management recommendations and the PCC
geographic location, primary specialty (e.g.
pharmacist, nurse, physician, other) or amount of
training of the respondent. We felt that the number of
potential respondents was so low (maximum 76), that
such sub-group analysis was unlikely to show any
statistical or clinical significance.
Similarly varied results in PCC management
recommendations have been reported previously
regarding enteric-coated aspirin ingestions.7 The lack
of clear consensus recommendations in both of these
surveys may stem from several
causes. For one thing, clinical
toxicology relies heavily on
anecdotal case experience. It
would not be ethical to conduct
controlled, prospective human
studies that produce significant
toxicity among the subjects. Since
case experience will vary widelyPage  59 The California Journal of Emergency Medicine V:3, Jul-Sep 2004
between practitioners, it is not surprising that their
recommendations will also vary. We additionally
suggest that the very nature of a telephone survey to
determine PCC recommendations could artificially
highlight any differences, when, in fact, clinical practice
is more consistent.
CONCLUSION
Considerable variation exists among the
recommendations given by PCCs in the United States
and Canada regarding the management of pediatric
benzocaine exposures. The general consensus among
our survey respondents was that: 1) the need for
observation or any interventions is related to the
estimated ingested dose, 2) patients evaluated in a
healthcare facility should receive some kind of
gastrointestinal decontamination, 3) patients should
be observed for several hours (between 2 to 4 hours),
4) the primary signs to observe for are cyanosis,
respiratory distress, and altered level of consciousness,
5) arterial blood gas sampling should be obtained on
cyanotic patients, even if asymptomatic, and 6)
antidotal treatment with methylene blue should be given
for methemoglobin levels at or above 20%.
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There has been increasing interest in the development
of universal health care coverage in the United States.1-
3 The most prominent of these calls has come from a
recent Institute of Medicine (IOM) report calling for
universal health care coverage in the United States by
2010.4 There are several key points made in this
report that are clearly worth consideration. Over a
series of five reports, the IOM Committee on
Consequences of Uninsurance made the following
conclusions:4
•  The number of uninsured individuals under age 65
is large, growing, and has persisted even during
periods of strong economic growth.
•   Uninsured children and adults do not receive the
care they need; they suffer from poorer health
and development, and are more likely to die early
than are those with coverage.
•   Even one uninsured person in a family can put the
financial stability and health of the whole family at
risk.
•   A community’s high uninsured rate can adversely
affect the overall health status of the community,
its health care institutions and providers, and the
access of its residents to certain services.
•  The estimated value across the population in healthy
years of life gained by providing health insurance